The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas

Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. We used tissue microarrays consis...

Full description

Saved in:
Bibliographic Details
Published inJournal of breast cancer Vol. 15; no. 2; pp. 172 - 180
Main Authors Jang, Se Min, Han, Hulin, Jang, Ki-Seok, Jun, Young Jin, Jang, Si-Hyong, Min, Kyueng-Whan, Chung, Min Sung, Paik, Seung Sam
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Breast Cancer Society 01.06.2012
한국유방암학회
Subjects
Online AccessGet full text
ISSN1738-6756
2092-9900
2092-9900
DOI10.4048/jbc.2012.15.2.172

Cover

Abstract Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis. Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively). GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.
AbstractList Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.PURPOSEGlucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas.We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.METHODSWe used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis.Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).RESULTSMembranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively).GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.CONCLUSIONGLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.
Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis. Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively). GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis.
Purpose: Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The aim of this study was to investigate GLUT1 expression in human breast tissues and invasive ductal carcinomas. Methods: We used tissue microarrays consisting of normal breast tissue, ductal hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastases. We examined GLUT1 expression in the microarrays by immunohistochemistry, reviewed the medical records and performed a clinicopathological analysis. Results: Membranous GLUT1 expression was observed in normal and tumor cells. GLUT1 expression was higher in ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis than in normal tissue and ductal hyperplasia (p=0.002). Of 276 invasive ductal carcinomas, 106 (38.4%) showed GLUT1 expression. GLUT1 expression was correlated with higher histologic grade (p<0.001), larger tumor size (p=0.025), absence of estrogen receptor (p<0.001), absence of progesterone receptor (p<0.001), and triple-negative phenotype (p<0.001). In univariate survival analysis, patients with GLUT1 expression had poorer overall survival and disease-free survival (p=0.017 and p=0.021, respectively, log-rank test). In multivariate survival analysis with the Cox proportional hazards model, GLUT1 expression was an independent prognostic factor of poorer overall survival and disease-free survival (p=0.017 and p=0.019, respectively). Conclusion: GLUT1 expression seems to play an important role in malignant transformation, and the glycolytic phenotype in invasive ductal carcinoma may indicate aggressive biological behavior and a worse prognosis. KCI Citation Count: 19
Author Chung, Min Sung
Paik, Seung Sam
Jang, Ki-Seok
Min, Kyueng-Whan
Jang, Si-Hyong
Jun, Young Jin
Han, Hulin
Jang, Se Min
AuthorAffiliation 1 Department of Surgery, Hanyang University College of Medicine, Seoul, Korea
Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
AuthorAffiliation_xml – name: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– name: 1 Department of Surgery, Hanyang University College of Medicine, Seoul, Korea
Author_xml – sequence: 1
  givenname: Se Min
  surname: Jang
  fullname: Jang, Se Min
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Hulin
  surname: Han
  fullname: Han, Hulin
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Ki-Seok
  surname: Jang
  fullname: Jang, Ki-Seok
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Young Jin
  surname: Jun
  fullname: Jun, Young Jin
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Si-Hyong
  surname: Jang
  fullname: Jang, Si-Hyong
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Kyueng-Whan
  surname: Min
  fullname: Min, Kyueng-Whan
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Min Sung
  surname: Chung
  fullname: Chung, Min Sung
  organization: Department of Surgery, Hanyang University College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Seung Sam
  surname: Paik
  fullname: Paik, Seung Sam
  organization: Department of Pathology, Hanyang University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22807934$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001671102$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kUFvEzEQhS1URNPCD-CCfOSSYHvt9fqCFKXQRqpEhMLZcryziZuNHWwnKP8eb0OrwgFZmjn4e--N9K7QhQ8eEHpPyYQT3nx6WNkJI5RNqJiUIdkrNGJEsbFShFygEZVVM66lqC_RVUoPhNS8kvINumSsIVJVfIS2yw3g2_5kQ3_KzuLFBnzIpz1gl_AsxAi9ydDiXy5v8HS9jpCSO4IvCxvf4kUIES9iWPuQisJ5PPdHMyD45mCz6fHMROt82Jn0Fr3uTJ_g3Z99jX58_bKc3Y3vv93OZ9P7seUVy2PTCkqhsdwy0SnacSOVUY1YEWsEIQKUrZq6vFaplnUdGCla0QjKO6AcSHWNPp59fez01jodjHvc66C3UU-_L-eaq7ohdUE_n9H9YbWD1oLP0fR6H93OxNOj8O8f7zbF5qirSgnJX2TtY_h5gJT1ziULfW88hEPSlDBJOKsJK-iHl1nPIU9lFICeARtDShG6Z4QSPRSuS-F6KFxTocuQg6n8R2NdNtmF4VzX_0f5GyStsj4
CitedBy_id crossref_primary_10_18632_oncotarget_4499
crossref_primary_10_1096_fj_202001415RR
crossref_primary_10_1007_s10911_013_9310_8
crossref_primary_10_1016_S0254_6272_17_30050_X
crossref_primary_10_1038_ncomms8882
crossref_primary_10_1097_MD_0000000000012961
crossref_primary_10_1016_j_biopha_2023_114435
crossref_primary_10_1016_j_leukres_2015_12_008
crossref_primary_10_1038_s41598_018_27303_6
crossref_primary_10_1111_cas_12240
crossref_primary_10_1159_000358365
crossref_primary_10_1007_s12010_023_04373_5
crossref_primary_10_3390_cancers14020437
crossref_primary_10_3389_fonc_2023_1094480
crossref_primary_10_1002_mc_22988
crossref_primary_10_1007_s00432_019_02847_w
crossref_primary_10_18632_oncotarget_17445
crossref_primary_10_1186_1471_2407_13_538
crossref_primary_10_4048_jbc_2015_18_1_1
crossref_primary_10_1186_s40644_020_00362_7
crossref_primary_10_1590_1806_9282_20221334
Cites_doi 10.1016/j.pharmthera.2008.09.005
10.1128/MCB.23.20.7315-7328.2003
10.1073/pnas.93.5.1847
10.1016/j.gde.2006.12.006
10.1111/j.1349-7006.2002.tb01214.x
10.1016/S0959-8049(00)00371-3
10.4048/jkbcs.2001.4.2.167
10.1016/j.humpath.2009.09.001
10.1590/S1807-59322011000600008
10.1007/s00432-009-0652-y
10.1126/science.123.3191.309
10.1038/nrc1478
10.5858/2007-131-18-ASOCCO
10.1016/0898-6568(93)90028-K
10.5858/134.6.907
10.3322/canjclin.56.1.37
10.1371/journal.pone.0023205
10.1074/jbc.M010144200
10.1007/s00428-010-0938-0
10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
10.1016/j.semcancer.2008.11.009
10.1016/S1607-551X(09)70320-1
10.1002/ijc.2910560503
10.4048/jkbcs.2001.4.2.161
10.1016/S0022-5347(01)67725-5
ContentType Journal Article
Copyright 2012 Korean Breast Cancer Society. All rights reserved. 2012
Copyright_xml – notice: 2012 Korean Breast Cancer Society. All rights reserved. 2012
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.4048/jbc.2012.15.2.172
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2092-9900
EndPage 180
ExternalDocumentID oai_kci_go_kr_ARTI_496806
PMC3395740
22807934
10_4048_jbc_2012_15_2_172
Genre Journal Article
GroupedDBID ---
5-W
5GY
8JR
8XY
9ZL
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
DU5
EF.
GROUPED_DOAJ
HYE
KQ8
M48
O5R
O5S
PGMZT
RPM
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c432t-ad511e8c4c25f91f4a79a985b0ca5005e9c386868d99d2ffea75d58514fe14e03
IEDL.DBID M48
ISSN 1738-6756
2092-9900
IngestDate Tue Nov 21 21:30:10 EST 2023
Thu Aug 21 14:01:44 EDT 2025
Fri Jul 11 08:52:08 EDT 2025
Thu Jan 02 22:10:13 EST 2025
Tue Jul 01 01:56:40 EDT 2025
Thu Apr 24 23:00:46 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Breast
Glucose transporter 1
Invasive ductal carcinoma
Prognosis
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c432t-ad511e8c4c25f91f4a79a985b0ca5005e9c386868d99d2ffea75d58514fe14e03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
G704-SER000010237.2012.15.2.012
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.4048/jbc.2012.15.2.172
PMID 22807934
PQID 1027042602
PQPubID 23479
PageCount 9
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_496806
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3395740
proquest_miscellaneous_1027042602
pubmed_primary_22807934
crossref_primary_10_4048_jbc_2012_15_2_172
crossref_citationtrail_10_4048_jbc_2012_15_2_172
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-06-01
PublicationDateYYYYMMDD 2012-06-01
PublicationDate_xml – month: 06
  year: 2012
  text: 2012-06-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of breast cancer
PublicationTitleAlternate J Breast Cancer
PublicationYear 2012
Publisher Korean Breast Cancer Society
한국유방암학회
Publisher_xml – name: Korean Breast Cancer Society
– name: 한국유방암학회
References Rathmell (10.4048/jbc.2012.15.2.172_ref4) 2003; 23
Gatenby (10.4048/jbc.2012.15.2.172_ref19) 2004; 4
Brown (10.4048/jbc.2012.15.2.172_ref14) 1993; 72
Ravazoula (10.4048/jbc.2012.15.2.172_ref26) 2003; 24
Ganapathy (10.4048/jbc.2012.15.2.172_ref20) 2009; 121
Young (10.4048/jbc.2012.15.2.172_ref5) 2011; 6
Zamora-León (10.4048/jbc.2012.15.2.172_ref21) 1996; 93
Semenza (10.4048/jbc.2012.15.2.172_ref7) 2009; 19
Merrall (10.4048/jbc.2012.15.2.172_ref17) 1993; 5
Warburg (10.4048/jbc.2012.15.2.172_ref3) 1956; 123
Schmidt (10.4048/jbc.2012.15.2.172_ref1) 2010; 136
Sakashita (10.4048/jbc.2012.15.2.172_ref11) 2001; 37
Chen (10.4048/jbc.2012.15.2.172_ref6) 2001; 276
Kuo (10.4048/jbc.2012.15.2.172_ref29) 2006; 22
Hammond (10.4048/jbc.2012.15.2.172_ref12) 2010; 134
Pinheiro (10.4048/jbc.2012.15.2.172_ref25) 2011; 26
Wolff (10.4048/jbc.2012.15.2.172_ref13) 2007; 131
Singletary (10.4048/jbc.2012.15.2.172_ref2) 2006; 56
Kim (10.4048/jbc.2012.15.2.172_ref27) 2001; 4
Carvalho (10.4048/jbc.2012.15.2.172_ref9) 2011; 66
Younes (10.4048/jbc.2012.15.2.172_ref30) 1995; 15
Gordan (10.4048/jbc.2012.15.2.172_ref8) 2007; 17
Mellanen (10.4048/jbc.2012.15.2.172_ref15) 1994; 56
Kang (10.4048/jbc.2012.15.2.172_ref24) 2002; 93
Nagase (10.4048/jbc.2012.15.2.172_ref16) 1995; 153
Clavo (10.4048/jbc.2012.15.2.172_ref18) 1995; 36
Chen (10.4048/jbc.2012.15.2.172_ref22) 2010; 457
Park (10.4048/jbc.2012.15.2.172_ref10) 2010; 41
Ahn (10.4048/jbc.2012.15.2.172_ref28) 2001; 4
Hao (10.4048/jbc.2012.15.2.172_ref23) 2009; 40
11166147 - Eur J Cancer. 2001 Jan;37(2):204-9
19655166 - J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25
19292042 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):44-7
21870331 - Histol Histopathol. 2011 Oct;26(10):1279-86
8221565 - Cancer. 1993 Nov 15;72(10):2979-85
20524868 - Arch Pathol Lab Med. 2010 Jun;134(6):907-22
20526721 - Virchows Arch. 2010 Jul;457(1):53-61
18992769 - Pharmacol Ther. 2009 Jan;121(1):29-40
8700847 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52
15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9
7658223 - J Nucl Med. 1995 Sep;36(9):1625-32
21808860 - Clinics (Sao Paulo). 2011;66(6):965-72
19114105 - Semin Cancer Biol. 2009 Feb;19(1):12-6
8314336 - Int J Cancer. 1994 Mar 1;56(5):622-9
13298683 - Science. 1956 Feb 24;123(3191):309-14
14658600 - Eur J Gynaecol Oncol. 2003;24(6):544-6
11120745 - J Biol Chem. 2001 Mar 23;276(12):9519-25
17208433 - Curr Opin Genet Dev. 2007 Feb;17(1):71-7
21826239 - PLoS One. 2011;6(8):e23205
12417042 - Jpn J Cancer Res. 2002 Oct;93(10):1123-8
19548375 - Arch Pathol Lab Med. 2007;131(1):18-43
16849102 - Kaohsiung J Med Sci. 2006 Jul;22(7):339-45
8130071 - Cell Signal. 1993 Nov;5(6):667-75
16449185 - CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1
7861542 - J Urol. 1995 Mar;153(3 Pt 1):798-801
14517300 - Mol Cell Biol. 2003 Oct;23(20):7315-28
19954817 - Hum Pathol. 2010 Mar;41(3):431-7
8669885 - Anticancer Res. 1995 Nov-Dec;15(6B):2895-8
References_xml – volume: 121
  start-page: 29
  year: 2009
  ident: 10.4048/jbc.2012.15.2.172_ref20
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2008.09.005
– volume: 23
  start-page: 7315
  year: 2003
  ident: 10.4048/jbc.2012.15.2.172_ref4
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.23.20.7315-7328.2003
– volume: 93
  start-page: 1847
  year: 1996
  ident: 10.4048/jbc.2012.15.2.172_ref21
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.93.5.1847
– volume: 17
  start-page: 71
  year: 2007
  ident: 10.4048/jbc.2012.15.2.172_ref8
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2006.12.006
– volume: 93
  start-page: 1123
  year: 2002
  ident: 10.4048/jbc.2012.15.2.172_ref24
  publication-title: Jpn J Cancer Res
  doi: 10.1111/j.1349-7006.2002.tb01214.x
– volume: 37
  start-page: 204
  year: 2001
  ident: 10.4048/jbc.2012.15.2.172_ref11
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(00)00371-3
– volume: 4
  start-page: 167
  year: 2001
  ident: 10.4048/jbc.2012.15.2.172_ref28
  publication-title: J Korean Breast Cancer Soc
  doi: 10.4048/jkbcs.2001.4.2.167
– volume: 24
  start-page: 544
  year: 2003
  ident: 10.4048/jbc.2012.15.2.172_ref26
  publication-title: Eur J Gynaecol Oncol
– volume: 41
  start-page: 431
  year: 2010
  ident: 10.4048/jbc.2012.15.2.172_ref10
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2009.09.001
– volume: 66
  start-page: 965
  year: 2011
  ident: 10.4048/jbc.2012.15.2.172_ref9
  publication-title: Clinics (Sao Paulo)
  doi: 10.1590/S1807-59322011000600008
– volume: 36
  start-page: 1625
  year: 1995
  ident: 10.4048/jbc.2012.15.2.172_ref18
  publication-title: J Nucl Med
– volume: 136
  start-page: 219
  year: 2010
  ident: 10.4048/jbc.2012.15.2.172_ref1
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-009-0652-y
– volume: 123
  start-page: 309
  year: 1956
  ident: 10.4048/jbc.2012.15.2.172_ref3
  publication-title: Science
  doi: 10.1126/science.123.3191.309
– volume: 4
  start-page: 891
  year: 2004
  ident: 10.4048/jbc.2012.15.2.172_ref19
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1478
– volume: 131
  start-page: 18
  year: 2007
  ident: 10.4048/jbc.2012.15.2.172_ref13
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/2007-131-18-ASOCCO
– volume: 5
  start-page: 667
  year: 1993
  ident: 10.4048/jbc.2012.15.2.172_ref17
  publication-title: Cell Signal
  doi: 10.1016/0898-6568(93)90028-K
– volume: 134
  start-page: 907
  year: 2010
  ident: 10.4048/jbc.2012.15.2.172_ref12
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/134.6.907
– volume: 56
  start-page: 37
  year: 2006
  ident: 10.4048/jbc.2012.15.2.172_ref2
  publication-title: CA Cancer J Clin
  doi: 10.3322/canjclin.56.1.37
– volume: 6
  start-page: e23205
  year: 2011
  ident: 10.4048/jbc.2012.15.2.172_ref5
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0023205
– volume: 276
  start-page: 9519
  year: 2001
  ident: 10.4048/jbc.2012.15.2.172_ref6
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M010144200
– volume: 40
  start-page: 44
  year: 2009
  ident: 10.4048/jbc.2012.15.2.172_ref23
  publication-title: Sichuan Da Xue Xue Bao Yi Xue Ban
– volume: 457
  start-page: 53
  year: 2010
  ident: 10.4048/jbc.2012.15.2.172_ref22
  publication-title: Virchows Arch
  doi: 10.1007/s00428-010-0938-0
– volume: 26
  start-page: 1279
  year: 2011
  ident: 10.4048/jbc.2012.15.2.172_ref25
  publication-title: Histol Histopathol
– volume: 72
  start-page: 2979
  year: 1993
  ident: 10.4048/jbc.2012.15.2.172_ref14
  publication-title: Cancer
  doi: 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X
– volume: 19
  start-page: 12
  year: 2009
  ident: 10.4048/jbc.2012.15.2.172_ref7
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2008.11.009
– volume: 22
  start-page: 339
  year: 2006
  ident: 10.4048/jbc.2012.15.2.172_ref29
  publication-title: Kaohsiung J Med Sci
  doi: 10.1016/S1607-551X(09)70320-1
– volume: 15
  start-page: 2895
  issue: 6B
  year: 1995
  ident: 10.4048/jbc.2012.15.2.172_ref30
  publication-title: Anticancer Res
– volume: 56
  start-page: 622
  year: 1994
  ident: 10.4048/jbc.2012.15.2.172_ref15
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910560503
– volume: 4
  start-page: 161
  year: 2001
  ident: 10.4048/jbc.2012.15.2.172_ref27
  publication-title: J Korean Breast Cancer Soc
  doi: 10.4048/jkbcs.2001.4.2.161
– volume: 153
  start-page: 798
  year: 1995
  ident: 10.4048/jbc.2012.15.2.172_ref16
  publication-title: J Urol
  doi: 10.1016/S0022-5347(01)67725-5
– reference: 19292042 - Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 Jan;40(1):44-7
– reference: 19548375 - Arch Pathol Lab Med. 2007;131(1):18-43
– reference: 21870331 - Histol Histopathol. 2011 Oct;26(10):1279-86
– reference: 21826239 - PLoS One. 2011;6(8):e23205
– reference: 8700847 - Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1847-52
– reference: 15516961 - Nat Rev Cancer. 2004 Nov;4(11):891-9
– reference: 19655166 - J Cancer Res Clin Oncol. 2010 Feb;136(2):219-25
– reference: 16849102 - Kaohsiung J Med Sci. 2006 Jul;22(7):339-45
– reference: 16449185 - CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1
– reference: 8669885 - Anticancer Res. 1995 Nov-Dec;15(6B):2895-8
– reference: 14517300 - Mol Cell Biol. 2003 Oct;23(20):7315-28
– reference: 12417042 - Jpn J Cancer Res. 2002 Oct;93(10):1123-8
– reference: 19114105 - Semin Cancer Biol. 2009 Feb;19(1):12-6
– reference: 8130071 - Cell Signal. 1993 Nov;5(6):667-75
– reference: 8221565 - Cancer. 1993 Nov 15;72(10):2979-85
– reference: 11166147 - Eur J Cancer. 2001 Jan;37(2):204-9
– reference: 8314336 - Int J Cancer. 1994 Mar 1;56(5):622-9
– reference: 11120745 - J Biol Chem. 2001 Mar 23;276(12):9519-25
– reference: 14658600 - Eur J Gynaecol Oncol. 2003;24(6):544-6
– reference: 18992769 - Pharmacol Ther. 2009 Jan;121(1):29-40
– reference: 19954817 - Hum Pathol. 2010 Mar;41(3):431-7
– reference: 7861542 - J Urol. 1995 Mar;153(3 Pt 1):798-801
– reference: 17208433 - Curr Opin Genet Dev. 2007 Feb;17(1):71-7
– reference: 20524868 - Arch Pathol Lab Med. 2010 Jun;134(6):907-22
– reference: 7658223 - J Nucl Med. 1995 Sep;36(9):1625-32
– reference: 21808860 - Clinics (Sao Paulo). 2011;66(6):965-72
– reference: 13298683 - Science. 1956 Feb 24;123(3191):309-14
– reference: 20526721 - Virchows Arch. 2010 Jul;457(1):53-61
SSID ssj0064377
Score 2.0047977
Snippet Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been reported. The...
Purpose: Glucose uptake and glycolytic metabolism are enhanced in cancer cells, and increased expression of glucose transporter 1 (GLUT1) has also been...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 172
SubjectTerms Original
일반외과학
Title The Glycolytic Phenotype is Correlated with Aggressiveness and Poor Prognosis in Invasive Ductal Carcinomas
URI https://www.ncbi.nlm.nih.gov/pubmed/22807934
https://www.proquest.com/docview/1027042602
https://pubmed.ncbi.nlm.nih.gov/PMC3395740
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001671102
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Breast Cancer, 2012, 15(2), 60, pp.172-180
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Ra9swEBZdC2Uvo-u6NVsXNNhTIcGWZdl6GiVt1w4y8tBA34QsyW2aIHdOMpZ_vzvZCcsIg2GQMT6dsE5n3emO7wj5LHNTRNxikpS0Pe6YAJ1jBai7FikomGEB1Gf4XdyM-bf79H6PrMtbtRM43-naYT2pcT3r__qx-gIKD_ZrnyPs7FOBWIQx68dpH5oM_sgHsDEJ9MWGfBNUwBBVqLWSgY6DnSyaIOduFlvb1Atfl7ss0L8TKf_Yma6PyKvWpKQXzRp4TfacPyaHwzZo_oZMYSnQr7MViHwFJHT06HyFR690MqcDrM4xA4PTUjySpRcPwQFv_4FUe0tHVVXTUV1hSh70mHh6639qJKGXSwPzRgdYkMhjptEJGV9f3Q1uem2NhZ7hCVv0tAWLy-WGG5aWMi65zqSWeVpEoVZC6qRJcgGXldKysnQ6Sy2GEnnpYu6i5C3Z95V3p4SWRgA3l2nwiDgvoJNNRCFZrjmzsbAdEq2nVJkWgBzrYMwUOCIoBQVSUCgFFacKmox1yPmmy3ODvvEv4k8gJzU1E4WY2Xh_qNS0VuAZ3CouRR4JoFlLUYEeYXBEe1ct58CWZQGuH_i8a6S6GTJABsmEd0i2Je8NAY63_cZPHgNWd4JxUB69_58P-UBe4nOTkHZG9hf10n0E02dRdMORQTcs6244mfoN0tcB-g
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Glycolytic+Phenotype+is+Correlated+with+Aggressiveness+and+Poor+Prognosis+in+Invasive+Ductal+Carcinomas&rft.jtitle=Journal+of+breast+cancer&rft.au=Jang%2C+Se+Min&rft.au=Han%2C+Hulin&rft.au=Jang%2C+Ki-Seok&rft.au=Jun%2C+Young+Jin&rft.date=2012-06-01&rft.issn=1738-6756&rft.eissn=2092-9900&rft.volume=15&rft.issue=2&rft.spage=172&rft_id=info:doi/10.4048%2Fjbc.2012.15.2.172&rft.externalDBID=n%2Fa&rft.externalDocID=10_4048_jbc_2012_15_2_172
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-6756&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-6756&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-6756&client=summon